Magnetic resonance spectroscopic imaging (MRSI) can be used in glioma patients to map the metabolic alterations associated with IDH1,2 mutations that are central criteria for glioma diagnosis in the most recent classification 2021 WHO of brain tumors.1 The hallmark metabolic alteration of cancer IDH1,2 mutations is the de novo overproduction of d-2-hydroxyglutarate (2HG)2 as an “oncometabolite” that drives the epigenome3 and microenvironment4 toward tumor progression. This evidence concerns the gene IDH1 and neoplasm.